The increasing number and complexity of clinical trials,coupled with the recent increase in attention and enforcement from the U.S.Food and Drug Administration,arguably makes it more important than ever before that clinical investigators understand the regularatory requirements with which they must comply.This article outlines some of these requirements,common areas of non-compliance and FDA's enforcement options in dealing with such non-compliance.Finally,the article provides some suggestions for attaining and managing investigator compliance.
展开▼